Sector News

Teva laying off 500 at struggling sterile injectables plant in Hungary

May 17, 2017
Life sciences

Teva is giving up on its sterile injectables plant in Godollo, Hungary, that halted production after the FDA found manufacturing failings. The generics maker is laying off hundreds of workers in the next few months and will sell or close the plant by the end of next year.

Globes, citing reports in Hungarian media, says the generics maker will lay off about 500 workers in coming months but will continue limited production from the facility outside of Budapest. The company is working with authorities in Hungary as it searches for a buyer, the newspaper said. The decision does not affect Teva’s other operations in the country.

The report comes just weeks after Israeli media reported that financially struggling and management-challenged drugmaker was looking to cut up to 6,000 jobs. A company spokeswoman at the time confirmed plans to reduce costs, but said Teva “does not have a headcount target” because the number of job cuts would depend on the “right-sizing of each individual area of our business.”

The FDA last fall issued a warning letter that cited concerns about sterility and contamination issues at the plant and gave the company a long list of marching orders that it said had to be completed before the plant will be allowed to again ship product to the U.S.

Teva at the time said it was working diligently to address all of the FDA concerns, while also is working to replenish critical and priority products as quickly as possible. It said manufacturing for some products might be moved to other suppliers. A spokesperson could not be reached today.

The plant, which Teva opened in 2012 to expand its injected drug capacity, suspended production in February after an FDA inspection that uncovered the problems. The FDA last May put the plant on its import alert list, banning all but two drugs–the cancer treatment bleomycin and antibiotic amikacin, which were exempted to avoid shortages. Teva recalled all other unexpired drugs that were still in the U.S.

By Eric Palmer

Source: Fierce Pharma

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).